| Revision as of 07:15, 1 September 2011 editBogBot (talk | contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot← Previous edit |
Latest revision as of 01:21, 9 September 2024 edit undoUtopes (talk | contribs)Extended confirmed users, Page movers, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers38,715 edits chlorites temp |
| (49 intermediate revisions by 33 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
|
{{cs1 config|name-list-style=vanc}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 351491335 |
|
| verifiedrevid = 447812760 |
|
| IUPAC_name = Molecular oxygen tetrachlorite hydrate |
|
| IUPAC_name = Molecular oxygen tetrachlorite hydrate |
|
| image = Tetrachlorodecaoxide.png |
|
| image = |
|
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data--> |
|
| tradename = |
|
| tradename = |
|
| routes_of_administration = Topical, intravenous |
|
| routes_of_administration = |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = 92047-76-2 |
|
| CAS_number = 92047-76-2 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 549BT7IE1Q |
|
| PubChem = 3000391 |
|
| PubChem = 3000391 |
|
|
| ATC_prefix = D03 |
|
|
|
|
|
| ATC_suffix = AX11 |
|
<!--Chemical data--> |
|
|
| chemical_formula = |
|
|
| H=2 | Cl=4 | O=11 | charge = -4 |
|
|
| molecular_weight = 319.82 g/mol |
|
|
}} |
|
}} |
|
|
"'''Tetrachlorodecaoxide'''" (TCDO) is a chlorite-containing substance with claimed immunomodulatory, macrophage-activating properties.<ref>{{cite journal | vauthors = Maraprygsavan P, Mongkolsuk J, Arnhold J, Kuehne FW | title = The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glucose control in diabetes patients with severe foot syndrome | journal = Journal of Clinical & Translational Endocrinology | volume = 4 | pages = 53–58 | date = June 2016 | pmid = 29159131 | pmc = 5680448 | doi = 10.1016/j.jcte.2016.05.001 }}</ref> WF10 (Macrokine, Immunokine, Oxoferin) is an aqueous solution of tetrachlorodecaoxide designed for intravenous injection.<ref name="informa.com"/> Tetrachlorodecaoxide/WF10 were originally developed by Oxo Chemie.<ref>{{cite web|url=http://oxothai.com/about-us/ |archive-url=https://web.archive.org/web/20161220173657/http://oxothai.com/about-us/ |archive-date=2016-12-20 |title=About Us |website=OXO Chemie (Thai) |access-date=2016-12-20}}</ref> The chemical formula is given as Cl<sub>4</sub>H<sub>2</sub>O<sub>11</sub><sup>4-</sup>.<ref>{{cite web|url=https://pubchem.ncbi.nlm.nih.gov/compound/Tetrachlorodecaoxide|title=Tetrachlorodecaoxide - Cl4H2O11-4 |work = PubChem | publisher = U.S. National Library of Medicine |access-date=2016-12-20}}</ref><ref name="informa.com">{{cite web|url=http://drugprofiles.informa.com/drug_profiles/16509-wf10|title=WF10 |website=Drugprofiles.informa.com|access-date=2016-12-20}}</ref> This incomplete formula shows a mixture of ] ion, water, and molecular oxygen: "Cl<sub>4</sub>H<sub>2</sub>O<sub>11</sub><sup>4-</sup>" = 4ClO<sub>2</sub><sup>−</sup> + H<sub>2</sub>O + O<sub>2</sub>. Oxoferin was found to be equivalent with aqueous sodium chlorite.<ref>{{cite journal | vauthors = Habermann E, Müller B | title =Oxoferin und Natriumchlorit — Ein Vergleich |trans-title=Oxoferin and sodium chlorite — a comparison | journal = Klinische Wochenschrift | volume = 67 | pages = 20–25 | date = Jan 1989 | issue =1 | pmid = 2921839 | doi = 10.1007/bf01736530 |language=de}}</ref> |
|
'''Tetrachlorodecaoxide''' (TCDO) is a ] containing drug used for the dressing of ], ] and as ] protective agent. It is the active principle of the drug Oxoferin made by Brookes Pharmaceutical Laboratories (Pakistan) Ltd under license from Oxo Chemie GmbH. In May 2002, Oxo Chemie was acquired by Dimethaid Research Inc, (now Nuvo Research Inc). |
|
|
|
|
|
==Mode of action== |
|
|
Several chlorooxygen compounds, ] and reducing molecules in the presence of ] iron (]) are oxidants of biological relevance. ] of the ] has such iron and activates TCDO. It is available as sterile solution for topical use in 1:55 ]. Due to its oxidizing properties, TCDO can destroy most ] although it is not regarded as ]. But the main reason for its use for dressing of wounds is not its ] activity. This drug is regarded as ], that is, it acts by stimulating the immune system of the body. Tetrachlorodecaoxide combines with the ] part of ], ] and ], forming a TCDO-haemo complex. This in turn activates the ] and accelerates the process of ] which engulfs most of the ] and cell debris present on the surface of the wound, thus cleaning the wound surface and helping in the regenerative process. Tetrachlorodecaoxide is also ]ic and ]. The mitogenic impulse gives rise to two factors, MDGF(]) and WAF (]). The MDGF deposits ] and synthesizes ] fibers which fills the gap in the wounds, the WAF helps in the formation of new capillaries which further enhances the ] process. The chemotactic impulse acts on the ] (muscle cell) and causes it to contract, thereby bringing the wound edges closer and reducing the wound surface. Simultaneous influence of all these factors accelerate the wound healing with minimal scarring. <ref> (archived from on 2008-07-19)</ref> |
|
|
|
|
|
WF 10 is a 1 : 10 dilution of tetrachlorodecaoxide (TCDO) formulated for ]. It was developed by Oxo Chemie in ] as an adjunctive therapy to combination ] and ] prophylaxis regimens in ] patients. WF 10 specifically targets ]. WF10 potentially modulates disease-related up-regulation of immune responses both in vitro and in vivo. Thus immune response is influenced in a way that inappropriate inflammatory reactions are downregulated.<ref>Arzneimittelforschung. 2001;51(7):554-62. Chlorite-hemoprotein interaction as key role for the pharmacological activity of the chlorite-based drug WF10.Schempp H, Reim M, Dornisch K, Elstner EF. Institute of Phytopathology, Technical University Munich, Freising, Germany. h.schempp@flg.tum.de. ]</ref>. WF10 is currently being studied in the ], ] and ] for treatment of late-stage ] disease, as well as recurrent ], late post-radiation cystitis, ] and chronic active ] disease.<ref>McGrath MS, Kahn JO, Herndier BG. Development of WF10, a novel macrophage-regulating agent. Curr Opin Investig Drugs. 2002 Mar;3(3):365-73.]</ref> |
|
|
|
|
|
Oxo Chemie has worldwide ] rights to WF 10 and Dimethaid Research has an exclusive license for marketing and distribution in ]. WF 10 is approved for use in ] under the name IMMUNOKINE in patients with postradiation chronic inflammatory disease including ], ] and ].<ref>WF 10: Macrokine, TCDO, Tetrachlorodecaoxide. Author: Adis International Limited. Source: Drugs in R&D, Volume 5, Number 4, 2004 , pp. 242–244(3). Publisher: Adis International.]</ref> |
|
|
|
|
|
Tetrachlorodecaoxide produces ] even if diluted 500 fold, and leads to additional alterations if added in high concentrations to ].<ref>Klin Wochenschr. 1989 Jan 4;67(1):20-5. Oxoferin and sodium chlorite--a comparison. Habermann E, Müller B. Rudolf-Buchheim-Institut für Pharmakologie, Justus-Liebig-Universität, Giessen.]</ref> |
|
|
|
|
|
|
|
Tetrachlorodecaoxide / WF10 is used in the management of radiation cystitis,<ref>{{cite journal | vauthors = Smit SG, Heyns CF | s2cid = 29208541 | title = Management of radiation cystitis | journal = Nature Reviews. Urology | volume = 7 | issue = 4 | pages = 206–14 | date = April 2010 | pmid = 20212517 | doi = 10.1038/nrurol.2010.23 | hdl = 10019.1/14211 | url = http://scholar.sun.ac.za/bitstream/10019.1/14211/1/smit_management_2010.pdf | hdl-access = free }}</ref> is effective in the treatment of diabetic foot ulcers,<ref>{{cite journal | vauthors = Yingsakmongkol N | title = Clinical outcomes of WF10 adjunct to standard treatment of diabetic foot ulcers | journal = Journal of Wound Care | volume = 22 | issue = 3 | pages = 130–2, 134–6 | date = March 2013 | pmid = 23665731 | doi = 10.12968/jowc.2013.22.3.130 }}</ref> and is used in wound healing, where the mechanism of action is activation of the macrophage system, and increasing the partial pressure of oxygen in the wound.<ref>{{cite journal | vauthors = Parikh R, Bakhshi G, Naik M, Gaikwad B, Jadhav K, Tayade M | title = The Efficacy and Safety of Tetrachlorodecaoxide in Comparison with Super-oxidised Solution in Wound Healing | journal = Archives of Plastic Surgery | volume = 43 | issue = 5 | pages = 395–401 | date = September 2016 | pmid = 27689045 | pmc = 5040840 | doi = 10.5999/aps.2016.43.5.395 }}</ref> |
|
==Synonym== |
|
|
Ancloximex, |
|
|
Animexan, |
|
|
Balneozoon, |
|
|
Dermazoon, |
|
|
DesoPur, |
|
|
HydroXan, |
|
|
LegioCid, |
|
|
Oxilium, |
|
|
Oxocebron, |
|
|
Oxoferin, |
|
|
Oxomexan, |
|
|
Oxovasin, |
|
|
Oxovir, |
|
|
Oxoviron, |
|
|
Ryoxon , |
|
|
WF10.<ref></ref> |
|
|
|
|
|
|
==See also== |
|
== References == |
|
|
{{Reflist}} |
|
*] |
|
|
*] |
|
|
*] |
|
|
*] |
|
|
*] |
|
|
*] or Highly active antiretroviral therapy |
|
|
|
|
|
|
⚫ |
== External links == |
|
==References== |
|
|
|
* |
|
<references/> |
|
|
|
|
|
|
|
{{Chlorites}} |
| ⚫ |
==External links== |
|
|
* |
|
|
* (archived from on 2008-05-04) |
|
|
*{{ChemID|92047-76-2}} |
|
|
|
|
|
|
] |
|
] |
|
] |
|
] |